GLP-1 (Semaglutide): Reduces appetite Slows gastric emptying Increases satiety Supports sustainable calorie reduction Average weight loss: Up to 15% in 68 weeks (NEJM 2021) GLP-1 + GIP (Tirzepatide): GLP-1 + GIP synergy boosts insulin sensitivity Enhances metabolic balance Further suppresses appetite and cravings Average weight loss: Up to 21% in 72 weeks (SURMOUNT-1) Compounded vs
however, both demonstrated improvements in glycemic control and body weight
No reliance should be placed on links to third party content
Never strike battery with any sharp edge parts Trim your nail or wear glove before taking battery Never open or deform folding edge of the cell Never Fall, hit, bend battery body Never disassemble the cells
By understanding the why behind the appearance of your medication, you can move past the initial uncertainty and focus on the sustainable lifestyle changes that lead to long-term success
GLP-1 RA therapy may be preferred for many individuals, as shown by increasing evidence from large retrospective studies on the benefits of GLP-1 RAs on cardiovascular, kidney, weight loss, and glucose lowering outcomes
